Clinical trials: Fatty Liver
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) includes benign hepatic simple steatosis (SS) and steatohepatitis (NASH), which is characterised by inflammation leading to fibrosis and cirrhosis.
- Trial name
- NCT01856465
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Johane Allard
Obesity & Overweight, Weight Loss
A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change
This prospective cohort study collected baseline data and followed up obese patients at their first visit to a weight loss clinic.
- Conditions
- Obesity & Overweight, Weight Loss, Metabolic Syndrome, Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07239167
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
NAFLD
Copeptin and Nonalcoholic Fatty Liver Disease
Copeptin, a surrogate marker for vasopressin, has been found to be elevated in metabolic disorders including obesity and diabetes, which are disorders both associated with nonalcoholic fatty liver disease (NAFLD), and therefore…
- Trial name
- NCT03254563
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
NAFLD, Diabetes Mellitus, Type 2
Liver Fat as a Dietary Target for Treating Cardiometabolic Disorders in Prediabetes and Type 2 Diabetes
The overall aim of this study is to investigate the long-term impact of a customized diet aimed at reducing liver fat specifically and a healthy Nordic diet on ectopic fat (liver, pancreatic and visceral) and cardiometabolic risk…
- Conditions
- NAFLD, Diabetes Mellitus, Type 2, PreDiabetes
- Trial name
- NAFLDiet (NCT04527965)
- Testing
- Customized diet to reduce liver fat, Healthy Nordic diet, Control
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Visceral Steatosis, Hiv
Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD
To determine the distribution of visceral fat in people living with HIV (PLHIV) with NAFLD by clinical anthropometric indicators (wais-to-hip ratio), lipid accumulation product (waist circumference and triglycerides) and…
- Conditions
- Visceral Steatosis, Hiv, NAFLD
- Trial name
- Theratech (NCT05359471)
- Testing
- Bone densitometry, Questionnaires, Review of medical chart
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Fatty Liver, Gestational Diabetes
Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy
The aim of this study is to evaluate the prevalence of metabolic syndrome, liver function abnormality and non-alcoholic fatty liver disease in early pregnancy patients, and the risk of pregnancy complications.
- Trial name
- NCT02276144
- Testing
- Liver ultrasound
- Where
- 3 sites in South Korea
- Volunteers
- 2,400 people
- Sponsor
- Seoul National University Hospital
Non-Alcoholic Fatty Liver Disease
Tocotrienol as a Treatment for Non-alcoholic Fatty Liver Disease
Vitamin E's potential in treating non-alcoholic fatty liver disease (NAFLD) is attributed to its antioxidant properties. While tocopherols have shown significant results in NAFLD management, the powerful properties of…
- Trial name
- NCT06596382
- Testing
- Tocotrienol rich-vitamin E
- Where
- Malaysia
- Volunteers
- 264 people
- Sponsor
- National University of Malaysia
Colorectal Cancer, Coffee
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery…
- Conditions
- Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis
- Trial name
- COMMENCER (NCT05692024)
- Testing
- Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Non-alcoholic Fatty Liver Disease
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00641524
- Testing
- Phlebotomy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Western Ontario, Canada
NAFLD, Liver Cirrhosis
Risk Factors for Advanced Fibrosis Among FLD Patients
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication.
- Conditions
- NAFLD, Liver Cirrhosis, Diabetes Mellitus, Type 2
- Trial name
- FLD_FU_HUS (NCT05971082)
- Testing
- Follow-up
- Where
- Finland
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
Non-Alcoholic Steatohepatitis
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic…
- Trial name
- NCT02314026
- Testing
- Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 140 people
- Sponsor
- Meridian Bioscience, Inc.
Non-alcoholic Fatty Liver Disease, Obesity
The Influence of Autophagy on Fatty Liver
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease worldwide. It is not known why only some obese subjects develop NAFLD.
- Trial name
- NCT01988441
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- Far Eastern Memorial Hospital
NASH With Fibrosis
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
This is a randomized, open-label, parallel-dosing, multi-center study to evaluate the safety and efficacy of rencofilstat as evidenced by assessing changes in the HepQuant Shunt Disease Severity Index Score (DSI), safety labs…
- Trial name
- ALTITUDE (NCT05461105)
- Testing
- rencofilstat, 75 mg, rencofilstat, 150mg, rencofilstat, 225 mg
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hepion Pharmaceuticals, Inc.
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one…
- Trial name
- NCT06309992
- Testing
- Survodutide
- Where
- 37 sites in United States, Spain
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
- Trial name
- NCT05604287
- Testing
- ID119031166M
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and…
- Trial name
- NCT06256289
- Testing
- Canagliflozin 100mg Tab, Metformin Hydrochloride
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ping Li,MD
Obesity, Non-Alcoholic Fatty Liver Disease
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
- Trial name
- ATM (NCT06571474)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with…
- Conditions
- MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD, NAFLD - Non-Alcoholic Fatty Liver Disease
- Trial name
- CHRONOMASLD (NCT06705868)
- Testing
- Diet-Time-restricted eating (TRE), Lifestyle Management
- Where
- Cyprus
- Volunteers
- 150 people
- Sponsor
- Cyprus University of Technology
Hepatobiliary Disorders, Non-alcoholic Steatohepatitis
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
- Trial name
- NCT02970942
- Testing
- Semaglutide
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S